CASI Pharmeceuticals

Product Pipeline

CASI 2016 Pipeline

ENMD-2076 is our proprietary orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase and currently in multiple Phase 2 trials.

2ME2 (2-methoxyestradiol) is an orally active compound that has anti-proliferative, anti-angiogenic and anti-inflammatory properties.

MARQIBO, already marketed in the U.S. by our partner, is indicated for the treatment of advanced Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

EVOMELA (melphalan) for injection is intended to be used as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. EVOMELA was granted approval by the FDA of its New Drug Application in March 2016.

ZEVALIN, also already marketed in the U.S. by our partner, is indicated for patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL).

We intend to develop these drugs for import drug registration in our greater China region. For the most up-to-date safety information about these drugs, please refer to our partner’s website www.sppirx.com and to:

http://www.marqibo.com

http://www.evomela.com

http://www.zevalin.com

About Us

A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.

Learn More

In the News

CASI's turnaround turns eastward; firm seeks to be Celgene of China

Read Article →

Poster

Antitumor activity, safety and predictive biomarker results of ENMD-2076 administered to patients with recurrent ovarian clear cell carcinoma (OCCC): A trial of the Princess Margaret Phase II Consortium

Download →

Poster

Senescence as a Mechanism of Resistance to Aurora Kinase Inhibition with ENMD-2076 in p53 mutated Triple-Negative Breast Cancer (TNBC) Models

Download →